Barclays
HAE icon

Barclays’s Haemonetics HAE Stock Holding History

Barclays’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-50,000
Closed -$4.48M – 7229
2018
Q2 		$4.48M Buy
+50,000
New +$4.22M ﹤0.01% 1812

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barclays's HAE Position: Q1 2026 in Review

Barclays reduced its Haemonetics (HAE) stake by 77% in Q1 2026, selling an estimated $6.26M and leaving 28,153 shares worth $1.59M. The position accounts for ﹤0.01% of the portfolio, ranked #2499.

Barclays first reported a position in HAE in Q2 2013 and has held it in 52 quarters since. The position peaked at $16.4M in Q2 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Barclays held 28,153 shares of Haemonetics worth $1.59M as of Q1 2026.
  • Barclays sold 96,076 Haemonetics shares in Q1 2026, an estimated $6.26M.
  • Haemonetics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2499 holding.
  • Barclays first reported a position in Haemonetics in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Haemonetics position peaked at $16.4M in Q2 2025.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.